BNP/CALL/ASTRAZENECA/13000/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 12:50:53 26/06/2024 pm IST | ||
| 0.51 EUR | +8.51% |
|
| Current month | +14.63% | ||
| 1 month | -2.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 0.51 | +8.51% |
| 25/24/25 | 0.47 | +4.44% |
| 24/24/24 | 0.45 | -4.26% |
| 21/24/21 | 0.47 | +14.63% |
| 20/24/20 | 0.41 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 12:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC836E |
| ISIN | DE000PC836E9 |
| Date issued | 30/04/2024 |
| Strike | 13,000 p |
| Maturity | 20/09/2024 (87 Days) |
| Parity | 10 : 1 |
| Emission price | 0.36 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.01 € |
| Spread % | 2.08% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Warrants
- Warrant
